Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-type p53 and Bcl-xL

Molecular Cancer Therapeutics

Volumn 4, Issue 7, 2005, Pages 1096-1104

  Bauer, Joshua A ^a   Trask, Douglas K ^a,e   Kumar, Bhavna ^a   Los, Gerrit ^d   Castro, Jason ^a   Lee, Julia Shin Jung ^b,c   Chen, Jianyong ^b   Wang, Shaomeng ^b,c   Bradford, Carol R ^a,c   Carey, Thomas E ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BH3 PROTEIN; CISPLATIN; GOSSYPOL DERIVATIVE; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARYNX; NICK END LABELING; ORGAN PRESERVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; STUDENT T TEST; TREATMENT FAILURE; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GOSSYPOL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR MIMICRY; MUTATION; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23144467530     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0081     Document Type: Article

References (47)

1. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20:435-9.
2. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev 1999;99:2451-66.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
4. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324:1685-90.
5. el-Deiry WS. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol 1998;227:121-37.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
7. Moll UM, Schramm LM. p53- an acrobat in tumorigenesis. Crit Rev Oral Biol Med 1998;9:23-37.
8. Wynford-Thomas D. p53: guardian of cellular senescence. J Pathol 1996;180:118-21.
9. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 1995;113:408-12.
10. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-61.
11. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
12. Kovach JS, Hartmann A, Blaszyk H, et al. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A 1996;93:1093-6.
13. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-9.
14. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-57.
15. Bradford CR, Zhu S, Poore J, et al. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg 1997;123:605-9.
16. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 1997;385:123-5.
17. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
18. Fan S, Smith ML, Rivet DJ II, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-54.
19. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;55:64-75.
20. Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1994;5 Suppl 1: 61-5.
21. Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene 1995;11:1389-94.
22. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001;34:55-61.
23. Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002;112:638-44.
24. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004;10:7757-63.
25. Carey TE. Head and neck tumor cell lines. In: Hay R, Gazdar A, Park J-G, editors. Atlas of human tumor cell lines. San Diego (CA): Academic Press, Inc.; 1994. p. 79-120.
26. Nakata B, Albright KD, Barton RM, Howell SB, Los G. Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol 1995;35:511-8.
27. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003;103:645-62.
28. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
29. Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 2001;60: 1153-60.
30. Bradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 1999;121:534-8.
31. Osford SM, Dallman CL, Johnson PW, Ganesan A, Packham G. Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr Med Chem 2004;11:1031-9.
32. Kitada S, Leone M, Sareth S, et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-64.
33. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005;4:13-21.
34. Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003;66:93-103.
35. Oliver CL, Miranda MB, Shangary S, et al. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 2005;4:23-31.
36. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 1994;54:1707-14.
37. Coyle T, Levante S, Shetler M, Winfield J. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol 1994;19:25-35.
38. Ligueros M, Jeoung D, Tang B, et al. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br J Cancer 1997;76:21-8.
39. Shidaifat F, Canatan H, Kulp SK, et al. Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-β. Cancer Lett 1996;107:37-44.
40. 1 phase of the cell cycle. Anticancer Res 1997; 17:1003-9.
41. Wang X, Wang J, Wong SC, et al. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci 2000;67:2663-71.
42. Hou DX, Uto T, Tong X, et al. Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch Biochem Biophys 2004;428:179-87.
43. Benz CC, Keniry MA, Ford JM, et al. Biochemical correlates of the antitumor and anti mitochondrial properties of gossypol enantiomers. Mol Pharmacol 1990;37:840-7.
44. Marcucci G, Stock W, Dai G, et al. G3139, a BCL-2 antisense oligonucleotide, in AML. Ann Hematol 2004;83 Suppl 1:S93-4.
45. Marshall J, Chen H, Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15:1274-83.
46. Tolcher AW, Kuhn J, Schwartz G, et al. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004; 10:5048-57.
47. van de Donk NW, de Weerdt O, Veth G, et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 2004;18:1078-84.